Amedeo Smart

Free Medical Literature Service


 

Amedeo

Ischemic Heart Disease

  Free Subscription

Articles published in
Lancet
    July 2021
  1. AL-JABI SW, Aldabe L, Alhaj-Asaad L, Thaher M, et al
    Assessment of drug interactions and their associated factors among patients with cardiovascular diseases: a cross-sectional study from the occupied Palestinian territory.
    Lancet. 2021;398 Suppl 1:S8.
    >> Share

  2. AFIFI T, Obeid M, Abdelati M, Almoqaid A, et al
    WHO/International Society of Hypertension risk prediction charts versus the UK Prospective Diabetes Study risk engine for cardiovascular risk assessment among patients with type 2 diabetes: a comparative study.
    Lancet. 2021;398 Suppl 1:S3.
    >> Share

    June 2021
  3. ARNETT DK
    Widespread diabetes screening for cardiovascular disease risk estimation.
    Lancet. 2021 Jun 2. pii: S0140-6736(21)00764.
    >> Share

  4. PYLYPCHUK R, Wells S, Kerr A, Poppe K, et al
    Cardiovascular risk prediction in type 2 diabetes before and after widespread screening: a derivation and validation study.
    Lancet. 2021 Jun 2. pii: S0140-6736(21)00572.
    >> Share

    May 2021
  5. CHRISTOFFERSEN M, Tybjaerg-Hansen A
    Targeting IL-6 in patients at high cardiovascular risk.
    Lancet. 2021 May 14. pii: S0140-6736(21)00985.
    >> Share

  6. KOO BK, Kang J, Park KW, Rhee TM, et al
    Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial.
    Lancet. 2021 May 14. pii: S0140-6736(21)01063.
    >> Share

  7. CHIARITO M, Stefanini GG
    Antiplatelet therapy for secondary prevention of cardiovascular disease: challenging the certainties.
    Lancet. 2021 May 14. pii: S0140-6736(21)01120.
    >> Share

  8. LANE R
    Roxana Mehran: driving force in women's cardiovascular health.
    Lancet. 2021 May 14. pii: S0140-6736(21)01100.
    >> Share

  9. VOGEL B, Acevedo M, Appelman Y, Bairey Merz CN, et al
    The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030.
    Lancet. 2021 May 14. pii: S0140-6736(21)00684.
    >> Share

  10. MOCUMBI AO
    Women's cardiovascular health: shifting towards equity and justice.
    Lancet. 2021 May 14. pii: S0140-6736(21)01017.
    >> Share


  11. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
    Lancet. 2021;397:1625-1636.
    >> Share

  12. KAHAN T
    Decisions about antihypertensive treatment should focus on reducing cardiovascular risk.
    Lancet. 2021;397:1598-1599.
    >> Share

    April 2021
  13. SIBBING D, Kastrati A
    Guided P2Y12 inhibitor therapy after percutaneous coronary intervention.
    Lancet. 2021;397:1423-1425.
    >> Share

  14. GALLI M, Benenati S, Capodanno D, Franchi F, et al
    Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Lancet. 2021;397:1470-1483.
    >> Share

    March 2021
  15. ERLINGE D, Maehara A, Ben-Yehuda O, Botker HE, et al
    Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study.
    Lancet. 2021;397:985-995.
    >> Share

    February 2021
  16. LANGLEY RE, Gilbert DC, Duong T, Clarke NW, et al
    Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.
    Lancet. 2021;397:581-591.
    >> Share

    January 2021
  17. KAURA A, Sterne JAC, Trickey A, Mayet J, et al
    Managing NSTEMI in older patients - Authors' reply.
    Lancet. 2021;397:371-372.
    >> Share

  18. CORDERO A, Rodriguez-Manero M, Bertomeu-Gonzalez V, Gonzalez-Juanatey JR, et al
    Managing NSTEMI in older patients.
    Lancet. 2021;397:370-371.
    >> Share

  19. VERSACI F, Frati G, Biondi-Zoccai G
    Managing NSTEMI in older patients.
    Lancet. 2021;397:370.
    >> Share

  20. D'ASCENZO F, De Filippo O, Gallone G, Mittone G, et al
    Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets.
    Lancet. 2021;397:199-207.
    >> Share

  21. TEMPLIN C, Di Vece D
    Risk scores in predicting adverse events following acute coronary syndrome.
    Lancet. 2021;397:172-173.
    >> Share

    December 2020
  22. JACKSON R, Wells S, Rodgers A
    Cardiovascular preventive strategies are not conflicting.
    Lancet. 2020;396:1879-1880.
    >> Share

    November 2020
  23. RAAL FJ, Mohamed F
    Never too old to benefit from lipid-lowering treatment.
    Lancet. 2020;396:1608-1609.
    >> Share

  24. GENCER B, Marston NA, Im K, Cannon CP, et al
    Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials.
    Lancet. 2020;396:1637-1643.
    >> Share

  25. SILVAIN J, Lattuca B, Beygui F, Range G, et al
    Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial.
    Lancet. 2020 Nov 12. pii: S0140-6736(20)32236.
    >> Share

  26. MORTENSEN MB, Nordestgaard BG
    Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years: a contemporary primary prevention cohort.
    Lancet. 2020 Nov 9. pii: S0140-6736(20)32233.
    >> Share

  27. MACKENZIE IS, Ford I, Nuki G, Hallas J, et al
    Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
    Lancet. 2020 Nov 6. pii: S0140-6736(20)32234.
    >> Share

    October 2020
  28. JEGER RV, Farah A, Ohlow MA, Mangner N, et al
    Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial.
    Lancet. 2020 Oct 19. pii: S0140-6736(20)32173.
    >> Share

  29. TAKAHASHI K, Serruys PW, Fuster V, Farkouh ME, et al
    Redevelopment and validation of the SYNTAX score II to individualise decision making between percutaneous and surgical revascularisation in patients with complex coronary artery disease: secondary analysis of the multicentre randomised controlled SYNT
    Lancet. 2020 Oct 8. pii: S0140-6736(20)32114.
    >> Share

  30. RAMCHAND J, Burrell LM
    Circulating ACE2: a novel biomarker of cardiovascular risk.
    Lancet. 2020;396:937-939.
    >> Share

    September 2020

  31. NCD Countdown 2030: pathways to achieving Sustainable Development Goal target 3.4.
    Lancet. 2020;396:918-934.
    >> Share

    August 2020
  32. KAURA A, Sterne JAC, Trickey A, Abbott S, et al
    Invasive versus non-invasive management of older patients with non-ST elevation myocardial infarction (SENIOR-NSTEMI): a cohort study based on routine clinical data.
    Lancet. 2020;396:623-634.
    >> Share

  33. BENDZ B, Aaberge L
    Acute coronary syndromes in older patients: does older age matter?
    Lancet. 2020;396:585-587.
    >> Share

  34. FERRARI R, Ford I, Fox K, Challeton JP, et al
    Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial.
    Lancet. 2020 Aug 28. pii: S0140-6736(20)31790.
    >> Share

  35. KIM HS, Kang J, Hwang D, Han JK, et al
    Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial.
    Lancet. 2020 Aug 28. pii: S0140-6736(20)31791.
    >> Share

  36. MACLAREN G
    In sepsis-induced heart failure, extracorporeal membrane oxygenation can provide support.
    Lancet. 2020;396:515-517.
    >> Share

  37. BRECHOT N, Hajage D, Kimmoun A, Demiselle J, et al
    Venoarterial extracorporeal membrane oxygenation to rescue sepsis-induced cardiogenic shock: a retrospective, multicentre, international cohort study.
    Lancet. 2020;396:545-552.
    >> Share

  38. SCHWALM JD, McCready T, Islam S, McKee M, et al
    Cardiovascular risk in hypertension: open questions about HOPE 4 - Authors' reply.
    Lancet. 2020;396:310-311.
    >> Share

  39. RICHARDS A
    Cardiovascular risk in hypertension: open questions about HOPE 4.
    Lancet. 2020;396:310.
    >> Share

  40. HENDRIKS M, van Andel J, Asiki G, Kyobutungi C, et al
    Cardiovascular risk in hypertension: open questions about HOPE 4.
    Lancet. 2020;396:309-310.
    >> Share

    July 2020
  41. COMBES A, Price S, Slutsky AS, Brodie D, et al
    Temporary circulatory support for cardiogenic shock.
    Lancet. 2020;396:199-212.
    >> Share

  42. MAFHAM MM, Spata E, Goldacre R, Gair D, et al
    COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England.
    Lancet. 2020 Jul 14. pii: S0140-6736(20)31356.
    >> Share

  43. CHI G, Marszalek J
    Differential effect of ticagrelor on irreversible harms in diabetes.
    Lancet. 2020;396:93.
    >> Share

    June 2020
  44. STRONGMAN H, Lyon AR, Dos Santos Silva I, Smeeth L, et al
    Cancer and cardiovascular disease - Authors' reply.
    Lancet. 2020;395:1904-1905.
    >> Share

  45. KNISELY JPS, Henry SA, Saba SG, Puckett LL, et al
    Cancer and cardiovascular disease.
    Lancet. 2020;395:1904.
    >> Share

  46. ALAM N, Wright AK, Ashcroft DM, Renehan AG, et al
    Cancer and cardiovascular disease.
    Lancet. 2020;395:1903-1904.
    >> Share


  47. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial.
    Lancet. 2020;395:1927-1936.
    >> Share

    May 2020
  48. BUGIARDINI R, Cenko E
    Sex differences in myocardial infarction deaths.
    Lancet. 2020 May 20. pii: S0140-6736(20)31049.
    >> Share

  49. WALLI-ATTAEI M, Joseph P, Rosengren A, Chow CK, et al
    Variations between women and men in risk factors, treatments, cardiovascular disease incidence, and death in 27 high-income, middle-income, and low-income countries (PURE): a prospective cohort study.
    Lancet. 2020 May 20. pii: S0140-6736(20)30543.
    >> Share

  50. HOLMES JL, Brake S, Docherty M, Lilford R, et al
    Emergency ambulance services for heart attack and stroke during UK's COVID-19 lockdown.
    Lancet. 2020 May 14. pii: S0140-6736(20)31031.
    >> Share

  51. BYRNE RA, Colleran R
    Aspirin for secondary prevention of cardiovascular disease.
    Lancet. 2020;395:1462-1463.
    >> Share

  52. CHIARITO M, Sanz-Sanchez J, Cannata F, Cao D, et al
    Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis.
    Lancet. 2020;395:1487-1495.
    >> Share

    April 2020
  53. GIMBEL M, Qaderdan K, Willemsen L, Hermanides R, et al
    Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.
    Lancet. 2020;395:1374-1381.
    >> Share

  54. SINNAEVE PR, Gevaert SA
    Antiplatelet strategies in ageing patients with acute coronary syndromes.
    Lancet. 2020;395:1319-1321.
    >> Share

    March 2020
  55. HERRETT E, Jackson R, Smeeth L
    Managing cardiovascular disease risk in hypertension - Authors' reply.
    Lancet. 2020;395:870.
    >> Share

  56. MCMANUS R, Constanti M, Floyd CN, Glover M, et al
    Managing cardiovascular disease risk in hypertension.
    Lancet. 2020;395:869-870.
    >> Share

    February 2020

  57. Accelerated surgery versus standard care in hip fracture (HIP ATTACK): an international, randomised, controlled trial.
    Lancet. 2020;395:698-708.
    >> Share

  58. DASA O, Ruzieh M
    Polypill for prevention of cardiovascular diseases.
    Lancet. 2020;395:414.
    >> Share

  59. ROSHANDEL G, Kamangar F, Marshall T, Cheng KK, et al
    Polypill for prevention of cardiovascular diseases - Authors' reply.
    Lancet. 2020;395:414-415.
    >> Share

  60. DIMMITT SB, Stampfer HG
    Polypill for prevention of cardiovascular diseases.
    Lancet. 2020;395:413-414.
    >> Share

    January 2020
  61. MORICE MC
    Patients with left main coronary artery disease: stent or surgery?
    Lancet. 2020;395:167-168.
    >> Share

    December 2019
  62. HOLM NR, Makikallio T, Lindsay MM, Spence MS, et al
    Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial.
    Lancet. 2019 Dec 23. pii: S0140-6736(19)32972.
    >> Share

  63. BRUNNER FJ, Waldeyer C, Ojeda F, Salomaa V, et al
    Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium.
    Lancet. 2019 Dec 3. pii: S0140-6736(19)32519.
    >> Share

  64. ROBINSON JG
    The next treatment paradigm in cardiovascular prevention?
    Lancet. 2019 Dec 3. pii: S0140-6736(19)32949.
    >> Share

    October 2019
  65. SUCHARD MA, Schuemie MJ, Krumholz HM, You SC, et al
    Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis.
    Lancet. 2019 Oct 24. pii: S0140-6736(19)32317.
    >> Share

  66. VANEZIS AP
    The broken promise of remote ischaemic conditioning.
    Lancet. 2019;394:1389-1390.
    >> Share

  67. VON BIRGELEN C, Buiten RA
    Superiority of biodegradable polymer sirolimus-eluting stents in STEMI.
    Lancet. 2019;394:1208-1210.
    >> Share

    September 2019
  68. ZHOU M, Wang H, Zeng X, Yin P, et al
    Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
    Lancet. 2019;394:1145-1158.
    >> Share

  69. ERLINGE D
    NIRS-intravascular imaging to predict coronary events.
    Lancet. 2019 Sep 26. pii: S0140-6736(19)32217.
    >> Share

  70. WAKSMAN R, Di Mario C, Torguson R, Ali ZA, et al
    Identification of patients and plaques vulnerable to future coronary events with near-infrared spectroscopy intravascular ultrasound imaging: a prospective, cohort study.
    Lancet. 2019 Sep 26. pii: S0140-6736(19)31794.
    >> Share

  71. HAUSENLOY DJ, Kharbanda RK, Moller UK, Ramlall M, et al
    Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial.
    Lancet. 2019 Sep 6. pii: S0140-6736(19)32039.
    >> Share

  72. READ SH, Wild SH
    Prevention of premature cardiovascular death worldwide.
    Lancet. 2019 Sep 2. pii: S0140-6736(19)32034.
    >> Share

  73. VRANCKX P, Valgimigli M, Eckardt L, Tijssen J, et al
    Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.
    Lancet. 2019 Sep 2. pii: S0140-6736(19)31872.
    >> Share

  74. YUSUF S, Joseph P, Rangarajan S, Islam S, et al
    Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study.
    Lancet. 2019 Sep 2. pii: S0140-6736(19)32008.
    >> Share

    August 2019
  75. IGLESIAS JF, Muller O, Heg D, Roffi M, et al
    Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial.
    Lancet. 2019 Aug 30. pii: S0140-6736(19)31877.
    >> Share

  76. THUIJS DJFM, Kappetein AP, Serruys PW, Mohr FW, et al
    Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial.
    Lancet. 2019 Aug 30. pii: S0140-6736(19)31997.
    >> Share

  77. TAGGART DP, Pagano D
    Expansion or contraction of stenting in coronary artery disease?
    Lancet. 2019 Aug 30. pii: S0140-6736(19)32040.
    >> Share

  78. SCHWALM JD, McCready T, Lopez-Jaramillo P, Yusoff K, et al
    A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial.
    Lancet. 2019 Aug 30. pii: S0140-6736(19)31949.
    >> Share

  79. JAFAR TH, Samad Z, Bloomfield GS
    Parallel community solutions for cardiovascular risk reduction.
    Lancet. 2019 Aug 30. pii: S0140-6736(19)31995.
    >> Share

  80. BHATT DL, Steg PG, Mehta SR, Leiter LA, et al
    Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.
    Lancet. 2019 Aug 30. pii: S0140-6736(19)31887.
    >> Share

  81. VALGIMIGLI M, Manavifar N
    Ticagrelor in patients with diabetes and previous PCI.
    Lancet. 2019 Aug 30. pii: S0140-6736(19)31957.
    >> Share

  82. STAFF AC
    Long-term cardiovascular health after stopping pre-eclampsia.
    Lancet. 2019 Aug 28. pii: S0140-6736(19)31993.
    >> Share

  83. NASLUND U, Ng N, Wennberg P, Norberg M, et al
    Patient-doctor engagement in cardiovascular prevention - Authors' reply.
    Lancet. 2019;394:e27.
    >> Share

  84. ANYFANTI P, Gkaliagkousi E, Douma S
    Patient-doctor engagement in cardiovascular prevention.
    Lancet. 2019;394:e26.
    >> Share

  85. RAY KK, Corral P, Morales E, Nicholls SJ, et al
    Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options.
    Lancet. 2019;394:697-708.
    >> Share

  86. GUPTA R, Wood DA
    Primary prevention of ischaemic heart disease: populations, individuals, and health professionals.
    Lancet. 2019;394:685-696.
    >> Share

  87. ROSHANDEL G, Khoshnia M, Poustchi H, Hemming K, et al
    Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
    Lancet. 2019;394:672-683.
    >> Share

  88. STRONGMAN H, Gadd S, Matthews A, Mansfield KE, et al
    Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases.
    Lancet. 2019 Aug 20. pii: S0140-6736(19)31674.
    >> Share

  89. BLAES AH, Shenoy C
    Is it time to include cancer in cardiovascular risk prediction tools?
    Lancet. 2019 Aug 20. pii: S0140-6736(19)31886.
    >> Share

  90. NASLUND U, Lundgren A, Vanoli D, Norberg M, et al
    Is intima-media thickness a predictor for cardiovascular risk? - Authors' reply.
    Lancet. 2019;394:381.
    >> Share

  91. GONZALEZ-CANTERO A, Gonzalez-Cantero J, Sanchez-Moya AI, Rodriguez-Padial L, et al
    Is intima-media thickness a predictor for cardiovascular risk?
    Lancet. 2019;394:380-381.
    >> Share

    July 2019
  92. HERRETT E, Gadd S, Jackson R, Bhaskaran K, et al
    Eligibility and subsequent burden of cardiovascular disease of four strategies for blood pressure-lowering treatment: a retrospective cohort study.
    Lancet. 2019 Jul 25. pii: S0140-6736(19)31359.
    >> Share

    June 2019
  93. BARNETT R
    Acute myocardial infarction.
    Lancet. 2019;393:2580.
    >> Share

  94. TIJSSEN RYG, de Winter RJ, Wykrzykowska JJ
    ABSORB IV: will the low rate of scaffold thrombosis persist?
    Lancet. 2019;393:2392.
    >> Share

  95. STONE GW, Ellis SG, Kereiakes DJ
    ABSORB IV: will the low rate of scaffold thrombosis persist? - Authors' reply.
    Lancet. 2019;393:2392-2393.
    >> Share

  96. RISSANEN TT, Uskela S, Eranen J, Mantyla P, et al
    Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial.
    Lancet. 2019 Jun 13. pii: S0140-6736(19)31126.
    >> Share

  97. GERSTEIN HC, Colhoun HM, Dagenais GR, Diaz R, et al
    Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
    Lancet. 2019 Jun 7. pii: S0140-6736(19)31149.
    >> Share

  98. OIKONOMOU EK, Antoniades C
    Detection of coronary inflammation - Authors' reply.
    Lancet. 2019;393:2199-2200.
    >> Share

    May 2019
  99. RABER I, McCarthy CP, Vaduganathan M, Bhatt DL, et al
    The rise and fall of aspirin in the primary prevention of cardiovascular disease.
    Lancet. 2019;393:2155-2167.
    >> Share

  100. FUDIM M, Ali-Ahmed F, Patel MR, Sobotka PA, et al
    Sham trials: benefits and risks for cardiovascular research and patients.
    Lancet. 2019;393:2104-2106.
    >> Share

  101. JEGER RV, Kaiser C, Gilgen N, Coslovsky M, et al
    Drug-coated balloons: room for development of BASKET-SMALL 2 - Authors' reply.
    Lancet. 2019;393:1934-1935.
    >> Share

  102. SAJADIEH A, Kumarathurai P, Jeppesen JL
    Drug-coated balloons: room for development of BASKET-SMALL 2.
    Lancet. 2019;393:1934.
    >> Share

  103. ALFONSO F, Guimaraes MG, Rivero F, Cuesta J, et al
    Drug-coated balloons: room for development of BASKET-SMALL 2.
    Lancet. 2019;393:1933-1934.
    >> Share

  104. SHAH R, Khan B
    The MATRIX trial.
    Lancet. 2019;393:1803.
    >> Share

  105. MEYER TM, Hollenbeck M, Kielstein JT
    The MATRIX trial.
    Lancet. 2019;393:1802-1803.
    >> Share

  106. PICCOLO R, Bonaa KH, Efthimiou O, Varenne O, et al
    Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials.
    Lancet. 2019 May 2. pii: S0140-6736(19)30474.
    >> Share

  107. JENSEN LO, Christiansen EH
    Are drug-eluting stents safer than bare-metal stents?
    Lancet. 2019 May 2. pii: S0140-6736(19)31000.
    >> Share

    April 2019
  108. MCCALL B
    Alemtuzumab to be restricted pending review, says EMA.
    Lancet. 2019;393:1683.
    >> Share

  109. MILLWOOD IY, Walters RG, Mei XW, Guo Y, et al
    Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 men and women in China.
    Lancet. 2019 Apr 4. pii: S0140-6736(18)31772.
    >> Share

    March 2019
  110. THE LANCET EDITORS
    Retraction-Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial.
    Lancet. 2019;393:1084.
    >> Share

  111. COSTACOU T, Guo J, Miller RG, Orchard TJ, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes.
    Lancet. 2019;393:985.
    >> Share

  112. RAWSHANI A, Sattar N, Franzen S, Rawshani A, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes - Authors' reply.
    Lancet. 2019;393:985-986.
    >> Share

  113. SNAITH JR, Holmes-Walker DJ, Girgis CM, Greenfield JR, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes.
    Lancet. 2019;393:984-985.
    >> Share

  114. BAX JJ, Di Carli M, Narula J, Delgado V, et al
    Multimodality imaging in ischaemic heart failure.
    Lancet. 2019;393:1056-1070.
    >> Share

  115. MCCRINDLE BW, Rowley AH
    Improving coronary artery outcomes for children with Kawasaki disease.
    Lancet. 2019 Mar 7. pii: S0140-6736(18)33133.
    >> Share

  116. HAMADA H, Suzuki H, Onouchi Y, Ebata R, et al
    Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised
    Lancet. 2019 Mar 7. pii: S0140-6736(18)32003.
    >> Share

    February 2019
  117. KIMURA T
    Can ultra-thin strut drug-eluting stents improve outcomes?
    Lancet. 2019 Feb 28. pii: S0140-6736(19)30286.
    >> Share

  118. ZAMAN A, de Winter RJ, Kogame N, Chang CC, et al
    Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial.
    Lancet. 2019 Feb 28. pii: S0140-6736(18)32467.
    >> Share

  119. MEHRAN R, Vogel B, Ortega R, Cooney R, et al
    The Lancet Commission on women and cardiovascular disease: time for a shift in women's health.
    Lancet. 2019 Feb 8. pii: S0140-6736(19)30315.
    >> Share

    December 2018
  120. NASLUND U, Ng N, Lundgren A, Fharm E, et al
    Visualization of asymptomatic atherosclerotic disease for optimum cardiovascular prevention (VIPVIZA): a pragmatic, open-label, randomised controlled trial.
    Lancet. 2018 Dec 3. pii: S0140-6736(18)32818.
    >> Share

    November 2018
  121. ZELNIKER TA, Wiviott SD, Raz I, Im K, et al
    SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
    Lancet. 2018 Nov 9. pii: S0140-6736(18)32590.
    >> Share

    October 2018
  122. COLOMBO A, Giannini F
    Encouraging data from ABSORB IV pave the way to new scaffolds.
    Lancet. 2018;392:1490-1491.
    >> Share

  123. STONE GW, Ellis SG, Gori T, Metzger DC, et al
    Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial.
    Lancet. 2018;392:1530-1540.
    >> Share

  124. WILLEIT P, Ridker PM, Nestel PJ, Simes J, et al
    Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.
    Lancet. 2018 Oct 4. pii: S0140-6736(18)31652.
    >> Share

  125. MAFHAM M, Preiss D
    HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?
    Lancet. 2018 Oct 1. pii: S0140-6736(18)32348.
    >> Share

  126. HERNANDEZ AF, Green JB, Janmohamed S, D'Agostino RB Sr, et al
    Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
    Lancet. 2018 Oct 1. pii: S0140-6736(18)32261.
    >> Share

    September 2018
  127. CAMENZIND E, Popovic B
    Are all drug-eluting stents created equal?
    Lancet. 2018 Sep 21. pii: S0140-6736(18)32334.
    >> Share

  128. VON BIRGELEN C, Zocca P, Buiten RA, Jessurun GAJ, et al
    Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, ran
    Lancet. 2018 Sep 21. pii: S0140-6736(18)32001.
    >> Share

  129. DEHGHAN M, Mente A, Rangarajan S, Sheridan P, et al
    Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study.
    Lancet. 2018 Sep 11. pii: S0140-6736(18)31812.
    >> Share

  130. HO HH, Ong PJL
    BASKET-SMALL 2: advancing DCB beyond in-stent restenosis.
    Lancet. 2018;392:802-804.
    >> Share

  131. LANSKY A, Wijns W, Xu B, Kelbaek H, et al
    Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial.
    Lancet. 2018 Sep 3. pii: S0140-6736(18)31649.
    >> Share

  132. PILGRIM T, Piccolo R, Heg D, Roffi M, et al
    Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial.
    Lancet. 2018;392:737-746.
    >> Share

    August 2018
  133. VRANCKX P, Valgimigli M, Juni P, Hamm C, et al
    Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, ope
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31858.
    >> Share

  134. CAPODANNO D, Angiolillo DJ
    Aspirin for primary prevention of cardiovascular disease.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31990.
    >> Share

  135. GAZIANO JM, Brotons C, Coppolecchia R, Cricelli C, et al
    Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31924.
    >> Share

  136. VALGIMIGLI M, Frigoli E, Leonardi S, Vranckx P, et al
    Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31714.
    >> Share

  137. ANGIOLILLO DJ
    Vascular access and antithrombotic therapy in patients with acute coronary syndrome.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31921.
    >> Share

  138. BLANKENBERG S, Neumann JT, Westermann D
    Diagnosing myocardial infarction: a highly sensitive issue.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31996.
    >> Share

  139. JEGER RV, Farah A, Ohlow MA, Mangner N, et al
    Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31719.
    >> Share

  140. SHAH ASV, Anand A, Strachan FE, Ferry AV, et al
    High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31923.
    >> Share

  141. OIKONOMOU EK, Marwan M, Desai MY, Mancio J, et al
    Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31114.
    >> Share

  142. MAHABADI AA, Rassaf T
    Imaging of coronary inflammation for cardiovascular risk prediction.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31716.
    >> Share

  143. MENTE A, O'Donnell M, Rangarajan S, McQueen M, et al
    Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study.
    Lancet. 2018;392:496-506.
    >> Share

  144. RAWSHANI A, Sattar N, Franzen S, Rawshani A, et al
    Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study.
    Lancet. 2018;392:477-486.
    >> Share

    July 2018
  145. THEKEN KN, Grosser T
    Weight-adjusted aspirin for cardiovascular prevention.
    Lancet. 2018 Jul 12. pii: S0140-6736(18)31307.
    >> Share

  146. DOWLING C, Firoozi S, Brecker S
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:28.
    >> Share

  147. FRANCIS DP, Al-Lamee R
    Percutaneous coronary intervention for stable angina in ORBITA - Authors' reply.
    Lancet. 2018;392:28-30.
    >> Share

  148. BANNING A, Redwood S
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:28.
    >> Share

  149. BAUER A, Rizas KD, Massberg S
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:27.
    >> Share

  150. REED GW, Kapadia SR
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:27-28.
    >> Share

  151. POCOCK SJ
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:26-27.
    >> Share

  152. BARAKAT MF, Simitsis P
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:26.
    >> Share

  153. TU T, Liu Q, Hu X, Zhou S, et al
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:25.
    >> Share

  154. MUTHALALY RG, Nerlekar N, Brown AJ
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:25-26.
    >> Share

  155. DEGRELL P, Picard F, Varenne O
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:25.
    >> Share

    June 2018
  156. PATEL T, Tesfaldet B, Chowdhury I, Kettermann A, et al
    Endpoints in diabetes cardiovascular outcome trials.
    Lancet. 2018;391:2412.
    >> Share

  157. MARIATHAS M, Curzen N
    Troponin assays: developing indications.
    Lancet. 2018;391:2398-2399.
    >> Share

  158. DEVEREAUX PJ, Duceppe E, Guyatt G, Tandon V, et al
    Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial.
    Lancet. 2018;391:2325-2334.
    >> Share

  159. IKEMURA N, Sawano M, Ueda I, Fukuda K, et al
    Consequence of reimbursement policy alteration for urgent PCI in Japan.
    Lancet. 2018;391:2208-2209.
    >> Share

    May 2018
  160. MONTAIGNE D, Coisne A, Marechal X, Lefebvre P, et al
    Daytime variations in perioperative myocardial injury - Authors' reply.
    Lancet. 2018;391:2106.
    >> Share

  161. SPADACCIO C, Dalby M, Danton MHD
    Daytime variations in perioperative myocardial injury.
    Lancet. 2018;391:2105-2106.
    >> Share

  162. LUCCHINETTI E, Zaugg M
    Daytime variations in perioperative myocardial injury.
    Lancet. 2018;391:2104-2105.
    >> Share

  163. BARTMAN CM, Oyama Y, Eckle T
    Daytime variations in perioperative myocardial injury.
    Lancet. 2018;391:2104.
    >> Share

  164. BRILAKIS ES, Edson R, Bhatt DL, Goldman S, et al
    Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial.
    Lancet. 2018 May 11. pii: S0140-6736(18)30801.
    >> Share

  165. PYLYPCHUK R, Wells S, Kerr A, Poppe K, et al
    Cardiovascular disease risk prediction equations in 400 000 primary care patients in New Zealand: a derivation and validation study.
    Lancet. 2018 May 4. pii: S0140-6736(18)30664.
    >> Share

  166. DAMEN JAAG, Hooft L, Moons KGM
    Contemporary cardiovascular risk prediction.
    Lancet. 2018 May 4. pii: S0140-6736(18)30842.
    >> Share

    April 2018
  167. DEHGHAN M, Mente A, Yusuf S
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple? - Authors' reply.
    Lancet. 2018;391:1681-1682.
    >> Share

  168. HANSEL B, Roussel R, Giral P
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1680.
    >> Share

  169. KLEBER ME, Delgado GE, Dawczynski C, Lorkowski S, et al
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1680-1681.
    >> Share

  170. CAO XP, Tan CC, Yu JT
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1679-1680.
    >> Share

  171. CARBONE S, Billingsley H, Abbate A
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1679.
    >> Share

  172. LORKOWSKI S, Richter M, Linseisen J, Watzl B, et al
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1678-1679.
    >> Share

  173. ROSSOUW JE, Prentice RL
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1677.
    >> Share

  174. BHOPAL RS, Misra A
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1677-1678.
    >> Share

  175. MANN J, Meerpohl J, Nishida C, McLean R, et al
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1676.
    >> Share

  176. REYNOLDS AN
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1676.
    >> Share

  177. KAHLEOVA H, Crosby L, Levin S, Barnard ND, et al
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1676-1677.
    >> Share

  178. CHU DK, Kim LH, Young PJ, Zamiri N, et al
    Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis.
    Lancet. 2018;391:1693-1705.
    >> Share

    March 2018
  179. ALKHALIL M
    Bioresorbable polymer drug-eluting stents.
    Lancet. 2018;391:936.
    >> Share

  180. KANDZARI DE, Mauri L, Koolen JJ, Doros G, et al
    Bioresorbable polymer drug-eluting stents - Authors' reply.
    Lancet. 2018;391:936-937.
    >> Share

  181. SHAH R
    Bioresorbable polymer drug-eluting stents.
    Lancet. 2018;391:935-936.
    >> Share

  182. MOTOVSKA Z, Bhatt DL
    12 months of DAPT after acute coronary syndrome still beats 6 months.
    Lancet. 2018 Mar 9. pii: S0140-6736(18)30612.
    >> Share

  183. HAHN JY, Song YB, Oh JH, Cho DK, et al
    6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
    Lancet. 2018 Mar 9. pii: S0140-6736(18)30493.
    >> Share

    February 2018
  184. HEAD SJ, Milojevic M, Daemen J, Ahn JM, et al
    Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data.
    Lancet. 2018 Feb 22. pii: S0140-6736(18)30423.
    >> Share

  185. BHATT DL
    CABG the clear choice for patients with diabetes and multivessel disease.
    Lancet. 2018 Feb 22. pii: S0140-6736(18)30424.
    >> Share

  186. PAULES CI, Subbarao K
    Influenza vaccination and prevention of cardiovascular disease mortality - Authors' reply.
    Lancet. 2018;391:427-428.
    >> Share

  187. CALDEIRA D, Ferreira JJ, Costa J
    Influenza vaccination and prevention of cardiovascular disease mortality.
    Lancet. 2018;391:426-427.
    >> Share

    January 2018
  188. JOBS A, Desch S, Thiele H
    Great expectations - Authors' reply.
    Lancet. 2018;391:306-307.
    >> Share

  189. LEMESLE G, Laine M, Pankert M, Puymirat E, et al
    Great expectations.
    Lancet. 2018;391:306.
    >> Share

  190. ANAND SS, Bosch J, Eikelboom JW, Connolly SJ, et al
    Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Lancet. 2018;391:219-229.
    >> Share

  191. BOCHATON T, Ovize M
    Circadian rhythm and ischaemia-reperfusion injury.
    Lancet. 2018;391:8-9.
    >> Share

  192. BROWN DL, Redberg RF
    Last nail in the coffin for PCI in stable angina?
    Lancet. 2018;391:3-4.
    >> Share

  193. GERBER RT, Gershlick AH
    A SENIOR moment? Bare-metal stents in elderly patients.
    Lancet. 2018;391:4-6.
    >> Share

    December 2017
  194. SCHUMACHER H, Mahfoud F, Bohm M
    Overestimation of cardiovascular outcome incidence - Authors' reply.
    Lancet. 2017;390:2547.
    >> Share

  195. YE Y, Fonseca R
    Overestimation of cardiovascular outcome incidence.
    Lancet. 2017;390:2546-2547.
    >> Share

  196. THURSTON GD, Newman JD
    Walking to a pathway for cardiovascular effects of air pollution.
    Lancet. 2017 Dec 5. pii: S0140-6736(17)33078.
    >> Share

  197. SINHARAY R, Gong J, Barratt B, Ohman-Strickland P, et al
    Respiratory and cardiovascular responses to walking down a traffic-polluted road compared with walking in a traffic-free area in participants aged 60 years and older with chronic lung or heart disease and age-matched healthy controls: a randomised, cr
    Lancet. 2017 Dec 5. pii: S0140-6736(17)32643.
    >> Share

  198. DE WINTER RJ, Katagiri Y, Asano T, Milewski KP, et al
    A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 tri
    Lancet. 2017 Dec 1. pii: S0140-6736(17)33103.
    >> Share

    November 2017
  199. RIDKER PM, MacFadyen JG, Everett BM, Libby P, et al
    Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.
    Lancet. 2017 Nov 13. pii: S0140-6736(17)32814.
    >> Share

  200. CONNOLLY SJ, Eikelboom JW, Bosch J, Dagenais G, et al
    Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Lancet. 2017 Nov 10. pii: S0140-6736(17)32458.
    >> Share

  201. PRABHAKARAN D, Anand S, Watkins D, Gaziano T, et al
    Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition.
    Lancet. 2017 Nov 3. pii: S0140-6736(17)32471.
    >> Share

  202. AL-LAMEE R, Thompson D, Dehbi HM, Sen S, et al
    Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial.
    Lancet. 2017 Nov 1. pii: S0140-6736(17)32714.
    >> Share

    October 2017
  203. VARENNE O, Cook S, Sideris G, Kedev S, et al
    Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial.
    Lancet. 2017 Oct 31. pii: S0140-6736(17)32713.
    >> Share

  204. MONTAIGNE D, Marechal X, Modine T, Coisne A, et al
    Daytime variation of perioperative myocardial injury in cardiac surgery and its prevention by Rev-Erbalpha antagonism: a single-centre propensity-matched cohort study and a randomised study.
    Lancet. 2017 Oct 26. pii: S0140-6736(17)32132.
    >> Share

  205. BYRNE RA, Schuster T
    Biodegradable polymer drug-eluting stents: caveat emptor.
    Lancet. 2017;390:1814-1816.
    >> Share

    September 2017
  206. LEAR SA, Hu W, Rangarajan S, Gasevic D, et al
    The effect of physical activity on mortality and cardiovascular disease in 130 000 people from 17 high-income, middle-income, and low-income countries: the PURE study.
    Lancet. 2017 Sep 21. pii: S0140-6736(17)31634.
    >> Share

    August 2017
  207. SIBBING D, Aradi D, Jacobshagen C, Gross L, et al
    Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Lancet. 2017 Aug 25. pii: S0140-6736(17)32155.
    >> Share

  208. RIDKER PM, MacFadyen JG, Thuren T, Everett BM, et al
    Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
    Lancet. 2017 Aug 25. pii: S0140-6736(17)32247.
    >> Share

  209. JINATONGTHAI P, Kongwatcharapong J, Foo CY, Phrommintikul A, et al
    Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis.
    Lancet. 2017;390:747-759.
    >> Share

    April 2017
  210. SHAH R
    Optical coherence tomography-guided PCI.
    Lancet. 2017;389:1607.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016